Nodality is an innovative biotechnology company advancing discovery, development and use of transformative therapies by revealing functional and systems biology. We focus on unmet medical needs in immunology, inflammation, cancer immunotherapy and oncology. Combining our expertise and proprietary technology, Single Cell Network Profiling, we deliver on the promise of precision medicine by increasing disease understanding, mapping drug activity, and developing tests for patient stratification to improve clinical outcomes for patients.

Nodality's industry-leading technology platform, Single Cell Network Profiling, or SCNP, analyzes pathway activities and responses at the single cell level, opening up significant opportunities for gaining new insights into disease biology and enabling better medicine.

04/11/2013 – Nodality, Inc. Announces Data Presentations at AACR 2013 Annual Meeting

04/09/2013 – Nodality, Inc. Announces Expansion of Company's Patent Estate

03/04/2013 – Nodality, Inc. Expands Senior Team, Appoints Guy Cavet, Ph.D., as Chief Information Officer, Head of Computational Sciences

09/24/2012 – Nodality, Inc. Appoints Laura Brege as Chief Executive Officer